Do the Effects of Wegovy Wear Off — and What Actually Happens Long-Term?

The biggest myth: that your body 'gets used to' Wegovy and it stops working

This is probably the most common concern people raise, and it deserves a direct answer. Semaglutide works by activating GLP-1 receptors that regulate appetite and slow gastric emptying, and you can read more about what semaglutide does to the body across multiple systems beyond just appetite. Unlike some medications, it does not appear to produce classical receptor tolerance, the mechanism that makes certain drugs progressively less effective at the same dose. In the STEP 1 trial, published in the New England Journal of Medicine, participants taking semaglutide 2.4 mg continued losing weight through most of the 68-week study period, with an average reduction of around 15% of body weight. The curve flattens rather than reverses: weight loss typically plateaus once you reach your new equilibrium, but that plateau is not the same as the medicine failing. A plateau is actually expected, it reflects your body settling at a lower weight where energy intake and expenditure balance again. If the plateau arrives sooner than expected or weight starts to creep back during active treatment, that is worth discussing with your prescriber, who can review the dose or explore other factors.

Understanding how Wegovy's effects work in practice helps set realistic expectations from the outset.

What happens when you stop, the regain question answered honestly

This is where the evidence is unambiguous, and frankly it is something every person starting treatment should know. When semaglutide is discontinued, the GLP-1 receptor activation that suppresses appetite stops. Hunger signals return, gastric emptying speeds back up, and (without the biological assist) most people find their food intake increases again. Clinical trial follow-up data consistently show that a substantial proportion of weight lost during treatment is regained within one to two years of stopping. This is not a personal failure or a sign the medicine did not work. It reflects the nature of obesity as a chronic condition rather than a course of treatment with a fixed end-point. The NICE appraisal of semaglutide (TA875) acknowledges this, which is partly why the NHS recommendation specifies use within specialist services with wraparound dietary and lifestyle support, the intention being to embed sustainable habits during the treatment window. If you are considering stopping, the conversation to have first is with your prescriber, not after.

For a broader look at semaglutide's effects beyond appetite alone, that page covers the physiology in more depth.

The end-of-week dip: temporary hunger versus genuine loss of effect

Many people notice a return of appetite in the 24 to 48 hours before their next injection is due. This is a normal pharmacokinetic pattern, not a sign the medicine is wearing off in any lasting sense. Semaglutide has a half-life of roughly one week, which means blood levels fall gradually in the days following each dose. A practical check you can do in under a minute: note on your phone whether hunger peaks on day six or seven, then settles again after the next injection. If that pattern holds, it is the end-of-week dip rather than tolerance. If hunger feels elevated throughout the whole week and does not settle after injection, that is a different conversation, one for your prescriber, who may review whether your current dose is still appropriate or whether a titration step is overdue. You can read more about the end-of-week effect specifically if that is what prompted this question.

Separately, if you are curious about how quickly the medicine gets going in the first place, the page on when Wegovy's effects begin covers the timeline from first dose to noticeable change.

What to do if the effects feel weaker on your current dose

A stalled loss or reduced appetite suppression partway through treatment usually has one of a few explanations: the dose has not yet been titrated to your maintenance level; a recent illness or missed injection has disrupted the steady-state blood concentration; or lifestyle factors (sleep, stress, alcohol) are working against the medicine's effect. The titration schedule exists precisely for this reason, treatment starts at a low dose to minimise side effects, then steps up through a prescriber-supervised process. Jumping ahead yourself is not safe; neither is concluding the medicine has failed before reaching a therapeutic dose. If you are weighing up cost alongside effectiveness, the cost context page for Wegovy explains what to look for in a clinically legitimate private prescription versus a cut-price listing that may not include the ongoing review you need. And if you want to see how semaglutide compares to other treatment options, the treatment overview sets out the landscape clearly. A named prescriber at a regulated UK pharmacy can review your progress and advise on next steps, that review is included as standard, with no extra fee.